|1.||Lundgren, Karen: 4 articles (03/2010 - 04/2009)|
|2.||Zhang, Hong: 3 articles (03/2010 - 04/2009)|
|3.||Burrows, Francis: 2 articles (03/2010 - 03/2010)|
|4.||Neely, Laura: 2 articles (03/2010 - 04/2009)|
|5.||Timple, Noel: 2 articles (03/2010 - 04/2009)|
|6.||Burrows, Francis J: 2 articles (08/2009 - 04/2009)|
|7.||Takeda, Tadashi: 1 article (01/2015)|
|8.||Ito, Yoshinori: 1 article (01/2015)|
|9.||Kimura, Hiroshi: 1 article (01/2015)|
|10.||Goshima, Fumi: 1 article (01/2015)|
|1.||Breast Neoplasms (Breast Cancer)
12/01/2013 - "6-Chloro-9-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethyl)-9H-purin-2-ylamine (BIIB021), a synthetic HSP90 inhibitor, exhibited promising antitumor activity in preclinical models and was in development for the treatment of breast cancer. "
01/01/2012 - "17-allylamino,17-demethoxygeldanamycin is the first Hsp90 inhibitor that has clinically been investigated in phase II trial, yielding promising results in patients with HER2-overexpressing metastatic breast cancer, whilst other Hsp90 inhibitors (retaspimycin HCL, NVP-AUY922, NVP-BEP800, CNF2024/BIIB021, SNX-5422, STA-9090, etc.) are currently under evaluation. "
01/15/2014 - "We performed a phase 1 trial of BIIB021 administered to subjects with advanced solid tumors. "
01/15/2014 - "A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors."
12/01/2013 - "Human plasma obtained from the phase I study in cancer patients were also analyzed to assess the metabolism of BIIB021 in humans and to ensure that selected animal species were exposed to all human major metabolites. "
10/03/2014 - "BIIB021 induces the apoptosis of various types of tumor cells in vitro and in vivo. "
01/15/2014 - "BIIB021 twice weekly, given with or without the 1 of 4-week rest period was tolerated in subjects with advanced solid tumors at doses that are pharmacodynamically active."
|3.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
10/03/2014 - "The aim of this study is to investigate the effect of BIIB021 on the radiosensitivity of esophageal squamous cell carcinoma (ESCC). "
10/03/2014 - "BIIB021, a novel Hsp90 inhibitor, sensitizes esophageal squamous cell carcinoma to radiation."
03/01/2010 - "BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy."
03/01/2010 - "A fully synthetic and bioavailable Hsp90 inhibitor, BIIB021, was evaluated for antitumor activity in a variety of head and neck squamous cell carcinoma (HNSCC) cell lines and HNSCC xenograft models, either as a single agent or in combination with fractionated radiation and the results were compared with that of 17-AAG. "
|4.||Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
01/01/2015 - "In this study, we evaluated the effects of BIIB021, a synthetic Hsp90 inhibitor, against EBV-positive and -negative T and NK lymphoma cell lines. "
01/01/2015 - "Moreover, BIIB021 might help to suppress EBV-positive T or NK cell lymphomas via the down-regulation of LMP1 expression. "
01/01/2015 - "These results suggest that BIIB021 has suppressive effects against T and NK lymphoma cells through the induction of apoptosis or a cell cycle arrest. "
01/01/2015 - "Finally, we evaluated the in vivo effects of the drug; BIIB021 inhibited the growth of EBV-positive NK cell lymphomas in a murine xenograft model. "
01/01/2015 - "The heat shock protein 90 inhibitor BIIB021 suppresses the growth of T and natural killer cell lymphomas."
|1.||6- chloro- 9- (4- methoxy- 3,5- dimethylpyridin- 2- ylmethyl)- 9H- purin- 2- ylamine
|4.||Biological Markers (Surrogate Marker)
|5.||Heat-Shock Proteins (Heat-Shock Protein)
|6.||Proteins (Proteins, Gene)
|7.||NK Cell Lectin-Like Receptor Subfamily K
|9.||HSP70 Heat-Shock Proteins (Heat-Shock Protein 70)
|1.||Heterologous Transplantation (Xenotransplantation)